Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash & Equivalents (2021 - 2025)

Aligos Therapeutics' Cash & Equivalents history spans 5 years, with the latest figure at $77.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 110.29% year-over-year to $77.8 million; the TTM value through Dec 2025 reached $77.8 million, up 110.29%, while the annual FY2025 figure was $77.8 million, 110.29% up from the prior year.
  • Cash & Equivalents reached $77.8 million in Q4 2025 per ALGS's latest filing, up from $41.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $239.7 million in Q3 2021 to a low of $24.2 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $107.2 million, with a median of $88.6 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 72.74% in 2024, then surged 470.99% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $186.8 million in 2021, then tumbled by 56.46% to $81.3 million in 2022, then soared by 66.82% to $135.7 million in 2023, then crashed by 72.74% to $37.0 million in 2024, then skyrocketed by 110.29% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Cash & Equivalents are $77.8 million (Q4 2025), $41.9 million (Q3 2025), and $122.9 million (Q2 2025).